StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a research note published on Friday morning. The brokerage issued a sell rating on the basic materials company’s stock.
Several other research analysts also recently commented on RKDA. Lake Street Capital raised shares of Arcadia Biosciences to a strong-buy rating in a research note on Tuesday, May 14th. HC Wainwright dropped their price objective on shares of Arcadia Biosciences from $10.00 to $6.00 and set a buy rating on the stock in a research note on Thursday, May 23rd.
Get Our Latest Analysis on RKDA
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The basic materials company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.74. Arcadia Biosciences had a negative net margin of 129.74% and a negative return on equity of 84.27%. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.20 million. During the same quarter in the prior year, the firm earned ($3.83) earnings per share. As a group, equities analysts expect that Arcadia Biosciences will post -2.29 EPS for the current year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Recommended Stories
- Five stocks we like better than Arcadia Biosciences
- What Is WallStreetBets and What Stocks Are They Targeting?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What is the Australian Securities Exchange (ASX)
- Why Call Options Volume for These 2 Stocks Spiked Together
- Insider Selling Explained: Can it Inform Your Investing Choices?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.